Siegfried and Celgene, the American bio-technology company, have put their existing close cooperation on a firm long-term footing. The agreement, which replaces a cooperation agreement signed in 2006, includes the acquisition of a production building in Pharmapark Siegfried in Zofingen, for which Celgene acquired rights of use including corresponding facilities 10 years ago.
Siegfried will continue to support Celgene in manufacturing pharmaceutical ingredients, intermediate products and analytics as well as in other technical services. Siegfried CEO Rudolf Hanko: “The close cooperation is attractive for both sides. Celgene benefits from Siegfried AG’s vast experience in the production of pharmaceutical ingredients, while Siegfried puts its customer relationship with one of the world’s most successful biotechnology companies on a firm long-term footing”.
Help employers find you! Check out all the jobs and post your resume.
Siegfried will continue to support Celgene in manufacturing pharmaceutical ingredients, intermediate products and analytics as well as in other technical services. Siegfried CEO Rudolf Hanko: “The close cooperation is attractive for both sides. Celgene benefits from Siegfried AG’s vast experience in the production of pharmaceutical ingredients, while Siegfried puts its customer relationship with one of the world’s most successful biotechnology companies on a firm long-term footing”.
Help employers find you! Check out all the jobs and post your resume.
